Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Controlled Study to Evaluate the Efficacy of Oral Probiotics Combined With PD-1 Monoclonal Antibody and Disitamab Vedotin in Bladder-Preserving Setting for Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer and Low Serum Butyrate

NCT07474064 is registered in ClinicalTrials.gov with chenxu as lead sponsor.

NCT NCT07474064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07474064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Controlled Study to Evaluate the Efficacy of Oral Probiotics Combined With PD-1 Monoclonal Antibody and Disitamab Vedotin in Bladder-Preserving Setting for Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer and Low Serum Butyrate
Lead sponsor
chenxu
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 26, 2026
Completion date
March 31, 2035
Enrollment
146 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

muscle invasive bladder cancer (mibc)